Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

Continuant
type: Class

Entity
type: Class

2024
type: Class

Generically Dependent Continuant
type: Class

individual
type: Document
rights: termsOfUse
date: 2026-08-22T10:41:16
publisher: Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
label: RDF description of Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register - http://research.umh.es/vivo/pub/articulo/277527

Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
type: Continuant
most specific type: Academic Article
type: Academic Article
type: Document
ARG_2000028: 277527 vcard
page end: 7
type: Entity
date time value: 277527 pubdate
page start: 1
most specific type: 2024
has publication venue: SEMINARS IN ARTHRITIS AND RHEUMATISM
related by: Autor:133301-Artículo:277527
type: Article
type: Information Content Entity
type: Anualidad
type: Generically Dependent Continuant
type: Thing
included: Medicina Clínica 2024
type: 2024

SEMINARS IN ARTHRITIS AND RHEUMATISM
type: Generically Dependent Continuant
type: Periodical
type: Continuant
type: Information Content Entity
type: Collection
type: Entity
type: Thing
type: Journal
publication venue for: Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

Autor:133301-Artículo:277527
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

Medicina Clínica 2024
type: Anualidad
type: 2024
type: DepartmentReport
type: Thing
type: ResearchReport
includes: Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register